To include your compound in the COVID-19 Resource Center, submit it here.

Bayer's Stivarga first to enter adaptive brain cancer trial

Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to enter the adaptive Phase II/III GBM AGILE trial, which has been designed to more rapidly identify

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE